Genetic Testing in Clinical Movement Disorders: A Case-Based Review

Lorraine V. Kalia; Graeme A. M. Nimmo; Tiago A. Mestre

doi:10.1055/s-0043-1763507

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2023; 43(01): 147-155
DOI: 10.1055/s-0043-1763507

Review Article

Genetic Testing in Clinical Movement Disorders: A Case-Based Review

Lorraine V. Kalia

¹Division of Neurology, Department of Medicine, Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic and Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada

,

Graeme A. M. Nimmo

²Fred A. Litwin Family Centre for Genetic Medicine, Department of Medicine, Mount Sinai Hospital and Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada

,

Tiago A. Mestre

³Division of Neurology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada

› Institutsangaben

Abstract

Genetics are fundamental to understanding the pathophysiology of neurological disease, including movement disorders. Genetic testing in clinical practice has changed dramatically over the last few decades. While the likelihood of establishing an etiological diagnosis is greater now with increased access to testing and more advanced technologies, clinicians face challenges when deciding whether to test, then selecting the appropriate test, and ultimately interpreting and sharing the results with patients and families. In this review, we use a case-based approach to cover core aspects of genetic testing for the neurologist, namely, genetic testing in Parkinson's disease, interpretation of inconclusive genetic test reports, and genetic testing for repeat expansion disorders using Huntington disease as a prototype.

Keywords

genetics - Huntington - movement disorders - Parkinson - repeat expansion - variable of unknown significance

Volltext

Referenzen

References
1 Capelle HH, Schrader C, Blahak C. et al. Deep brain stimulation for camptocormia in dystonia and Parkinson's disease. J Neurol 2011; 258 (01) 96-103
2 Wirdefeldt K, Gatz M, Reynolds CA, Prescott CA, Pedersen NL. Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol Aging 2011; 32 (10) 1923.e1-1923.e8
3 Cook L, Schulze J, Kopil C. et al. Genetic testing for Parkinson disease: are we ready?. Neurol Clin Pract 2021; 11 (01) 69-77
4 Fogel BL. Genetic and genomic testing for neurologic disease in clinical practice. Handb Clin Neurol 2018; 147: 11-22
5 Yang Y, Muzny DM, Xia F. et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014; 312 (18) 1870-1879
6 Gannamani R, van der Veen S, van Egmond M, de Koning TJ, Tijssen MAJ. Challenges in clinicogenetic correlations: one phenotype - many genes. Mov Disord Clin Pract (Hoboken) 2021; 8 (03) 311-321
7 Marras C, Lang A, van de Warrenburg BP. et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society task force. Mov Disord 2017; 32 (05) 724-725
8 Lange LM, Gonzalez-Latapi P, Rajalingam R. et al; on behalf of the Task Force on Genetic Nomenclature in Movement Disorders. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force - an update. Mov Disord 2022; 37 (05) 905-935
9 Sellbach AN, Boyle RS, Silburn PA, Mellick GD. Parkinson's disease and family history. Parkinsonism Relat Disord 2006; 12 (07) 399-409
10 Healy DG, Falchi M, O'Sullivan SS. et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (07) 583-590
11 Nalls MA, Duran R, Lopez G. et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013; 70 (06) 727-735
12 Mitsui J, Matsukawa T, Sasaki H. et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2015; 2 (04) 417-426
13 Sklerov M, Kang UJ, Liong C. et al. Frequency of GBA variants in autopsy-proven multiple system atrophy. Mov Disord Clin Pract (Hoboken) 2017; 4 (04) 574-581
14 Wernick AI, Walton RL, Koga S. et al. GBA variation and susceptibility to multiple system atrophy. Parkinsonism Relat Disord 2020; 77: 64-69
15 Oliveira LM, Rastin T, Nimmo GAM. et al. Occurrence of amyotrophic lateral sclerosis in type 1 Gaucher disease. Neurol Genet 2021; 7 (04) e600
16 Sanchez-Contreras M, Heckman MG, Tacik P. et al. Study of LRRK2 variation in tauopathy: progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2017; 32 (01) 115-123
17 Vilas D, Sharp M, Gelpi E. et al. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers. Mov Disord 2018; 33 (02) 335-338
18 Sidransky E, Nalls MA, Aasly JO. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361 (17) 1651-1661
19 Goldwurm S, Tunesi S, Tesei S. et al. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord 2011; 26 (11) 2144-2145
20 Hentati F, Trinh J, Thompson C, Nosova E, Farrer MJ, Aasly JO. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 2014; 83 (06) 568-569
21 Lee AJ, Wang Y, Alcalay RN. et al; Michael J. Fox LRRK2 Cohort Consortium. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov Disord 2017; 32 (10) 1432-1438
22 Anheim M, Elbaz A, Lesage S. et al; French Parkinson Disease Genetic Group. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78 (06) 417-420
23 Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med 2013; 15 (02) 146-149
24 Alcalay RN, Dinur T, Quinn T. et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71 (06) 752-757
25 Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson's disease: a kin cohort study. Mov Disord 2020; 35 (11) 2111-2114
26 Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 2020; 16 (02) 97-107
27 Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 2010; 31 (11) 1240-1250
28 Elsayed I, Martinez-Carrasco A, Cornejo-Olivas M, Bandres-Ciga S. Mapping the diverse and inclusive future of Parkinson's disease genetics and its widespread impact. Genes (Basel) 2021; 12 (11) 1681
29 Telenti A, Pierce LC, Biggs WH. et al. Deep sequencing of 10,000 human genomes. Proc Natl Acad Sci U S A 2016; 113 (42) 11901-11906
30 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
31 Harrison SM, Rehm HL. Is ‘likely pathogenic’ really 90% likely? Reclassification data in ClinVar. Genome Med 2019; 11 (01) 72
32 Susswein LR, Marshall ML, Nusbaum R. et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 2016; 18 (08) 823-832
33 Miller DT, Lee K, Chung WK. et al; ACMG Secondary Findings Working Group. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23 (08) 1381-1390
34 OMIM® - An Online Catalog of Human Genes and Genetic Disorders. Updated November 9, 2022. Accessed November 10, 2022, at: https://omim.org
35 Gupta PK, Bilmen JG, Hopkins PM. Anaesthetic management of a known or suspected malignant hyperthermia susceptible patient. BJA Educ 2021; 21 (06) 218-224
36 Ibañez K, Polke J, Hagelstrom RT. et al; WGS for Neurological Diseases Group, Genomics England Research Consortium. Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study. Lancet Neurol 2022; 21 (03) 234-245
37 Paulson H. Repeat expansion diseases. Handb Clin Neurol 2018; 147: 105-123
38 Losekoot M, van Belzen MJ, Seneca S, Bauer P, Stenhouse SA, Barton DE. European Molecular Genetic Quality Network (EMQN). EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet 2013; 21 (05) 480-486
39 Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord 1996; 11 (01) 111-114
40 Bean L, Bayrak-Toydemir P. American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet Med 2014; 16 (12) e2
41 Caron NS, Wright GEB, Hayden MR. Huntington Disease. In: Adam MP, Everman DB, Mirzaa GM. et al, eds. GeneReviews((R)). University of Washington, Seattle: Seattle (WA); 1993
42 Wild EJ, Mudanohwo EE, Sweeney MG. et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23 (05) 716-720
43 Castilhos RM, Souza AF, Furtado GV. et al. Huntington disease and Huntington disease-like in a case series from Brazil. Clin Genet 2014; 86 (04) 373-377
44 Hensman Moss DJ, Poulter M, Beck J. et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014; 82 (04) 292-299
45 Stevanin G, Fujigasaki H, Lebre AS. et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003; 126 (Pt 7): 1599-1603
46 Mariani LL, Tesson C, Charles P. et al. Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach. JAMA Neurol 2016; 73 (09) 1105-1114
47 Sułek-Piatkowska A, Krysa W, Zdzienicka E. et al. Searching for mutation in the JPH3, ATN1 and TBP genes in Polish patients suspected of Huntington's disease and without mutation in the IT15 gene. Neurol Neurochir Pol 2008; 42 (03) 203-209
48 Charles P, Camuzat A, Benammar N. et al; French Parkinson's Disease Genetic Study Group. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism?. Neurology 2007; 69 (21) 1970-1975